Drugs / US License Enbrel
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06392074 Comparator | Mar 2024 → May 2025 | — | mAbxience Research S.L. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | US License Enbrel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06392074 ↗ |
| Route | Subcutaneous | “Subcutaneous injection” NCT06392074 ↗ |